Distribution of clinical isolates of Candida spp. and antifungal susceptibility of high biofilm-forming Candida isolates

Detalhes bibliográficos
Autor(a) principal: Sahal,Gulcan
Data de Publicação: 2018
Outros Autores: Bilkay,Isil Seyis
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista da Sociedade Brasileira de Medicina Tropical
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822018000500644
Resumo: Abstract INTRODUCTION: The increase in the incidence of fungal infections, especially those caused by Candida albicans and other Candida species, necessitates the understanding and treatment of Candida-associated infections. In this study, we aimed to investigate the identification, distribution, and biofilm formation ability of different clinical Candida isolates and evaluate the distribution and antifungal susceptibilities of high biofilm-forming (HBF) Candida isolates. METHODS: For identification, carbohydrate fermentation, carbohydrate assimilation, and ChromAgar tests were used. Biofilm formation was assessed using crystal violet binding assay, while the susceptibility to antifungal agents was determined using ATBTM Fungus 3 test kits. RESULTS: The majority of Candida species were C. parapsilosis (31.3%; 31/99) and C. tropicalis (30.3%; 30/99). C. tropicalis was found to be the most frequently isolated species among all HBF Candida species. HBF Candida isolates were more frequently isolated from vaginal swab (35.7%; 10/28), tracheal aspirate (17.9%; 5/28), and urine (17.9%; 5/28). The majority of tested isolates were resistant to itraconazole and voriconazole, whereas no isolate was deemed resistant to 5-flucytosine. CONCLUSIONS: C. tropicalis displays the highest biofilm formation ability among all the Candida species evaluated, and HBF Candida isolates were more frequently seen in vaginal swab, tracheal aspirate, and urine samples. Our findings revealed that 5-flucytosine is the most efficient antifungal agent against HBF Candida isolates.
id SBMT-1_0a7b94d7ecf7aa6efbbdd23fd5bfff2d
oai_identifier_str oai:scielo:S0037-86822018000500644
network_acronym_str SBMT-1
network_name_str Revista da Sociedade Brasileira de Medicina Tropical
repository_id_str
spelling Distribution of clinical isolates of Candida spp. and antifungal susceptibility of high biofilm-forming Candida isolatesAntifungal resistanceBiofilm formationCandida albicansNon-Candida albicansCandida Species5-FlucytosineAbstract INTRODUCTION: The increase in the incidence of fungal infections, especially those caused by Candida albicans and other Candida species, necessitates the understanding and treatment of Candida-associated infections. In this study, we aimed to investigate the identification, distribution, and biofilm formation ability of different clinical Candida isolates and evaluate the distribution and antifungal susceptibilities of high biofilm-forming (HBF) Candida isolates. METHODS: For identification, carbohydrate fermentation, carbohydrate assimilation, and ChromAgar tests were used. Biofilm formation was assessed using crystal violet binding assay, while the susceptibility to antifungal agents was determined using ATBTM Fungus 3 test kits. RESULTS: The majority of Candida species were C. parapsilosis (31.3%; 31/99) and C. tropicalis (30.3%; 30/99). C. tropicalis was found to be the most frequently isolated species among all HBF Candida species. HBF Candida isolates were more frequently isolated from vaginal swab (35.7%; 10/28), tracheal aspirate (17.9%; 5/28), and urine (17.9%; 5/28). The majority of tested isolates were resistant to itraconazole and voriconazole, whereas no isolate was deemed resistant to 5-flucytosine. CONCLUSIONS: C. tropicalis displays the highest biofilm formation ability among all the Candida species evaluated, and HBF Candida isolates were more frequently seen in vaginal swab, tracheal aspirate, and urine samples. Our findings revealed that 5-flucytosine is the most efficient antifungal agent against HBF Candida isolates.Sociedade Brasileira de Medicina Tropical - SBMT2018-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822018000500644Revista da Sociedade Brasileira de Medicina Tropical v.51 n.5 2018reponame:Revista da Sociedade Brasileira de Medicina Tropicalinstname:Sociedade Brasileira de Medicina Tropical (SBMT)instacron:SBMT10.1590/0037-8682-0136-2018info:eu-repo/semantics/openAccessSahal,GulcanBilkay,Isil Seyiseng2019-07-29T00:00:00Zoai:scielo:S0037-86822018000500644Revistahttps://www.sbmt.org.br/portal/revista/ONGhttps://old.scielo.br/oai/scielo-oai.php||dalmo@rsbmt.uftm.edu.br|| rsbmt@rsbmt.uftm.edu.br1678-98490037-8682opendoar:2019-07-29T00:00Revista da Sociedade Brasileira de Medicina Tropical - Sociedade Brasileira de Medicina Tropical (SBMT)false
dc.title.none.fl_str_mv Distribution of clinical isolates of Candida spp. and antifungal susceptibility of high biofilm-forming Candida isolates
title Distribution of clinical isolates of Candida spp. and antifungal susceptibility of high biofilm-forming Candida isolates
spellingShingle Distribution of clinical isolates of Candida spp. and antifungal susceptibility of high biofilm-forming Candida isolates
Sahal,Gulcan
Antifungal resistance
Biofilm formation
Candida albicans
Non-Candida albicans
Candida Species
5-Flucytosine
title_short Distribution of clinical isolates of Candida spp. and antifungal susceptibility of high biofilm-forming Candida isolates
title_full Distribution of clinical isolates of Candida spp. and antifungal susceptibility of high biofilm-forming Candida isolates
title_fullStr Distribution of clinical isolates of Candida spp. and antifungal susceptibility of high biofilm-forming Candida isolates
title_full_unstemmed Distribution of clinical isolates of Candida spp. and antifungal susceptibility of high biofilm-forming Candida isolates
title_sort Distribution of clinical isolates of Candida spp. and antifungal susceptibility of high biofilm-forming Candida isolates
author Sahal,Gulcan
author_facet Sahal,Gulcan
Bilkay,Isil Seyis
author_role author
author2 Bilkay,Isil Seyis
author2_role author
dc.contributor.author.fl_str_mv Sahal,Gulcan
Bilkay,Isil Seyis
dc.subject.por.fl_str_mv Antifungal resistance
Biofilm formation
Candida albicans
Non-Candida albicans
Candida Species
5-Flucytosine
topic Antifungal resistance
Biofilm formation
Candida albicans
Non-Candida albicans
Candida Species
5-Flucytosine
description Abstract INTRODUCTION: The increase in the incidence of fungal infections, especially those caused by Candida albicans and other Candida species, necessitates the understanding and treatment of Candida-associated infections. In this study, we aimed to investigate the identification, distribution, and biofilm formation ability of different clinical Candida isolates and evaluate the distribution and antifungal susceptibilities of high biofilm-forming (HBF) Candida isolates. METHODS: For identification, carbohydrate fermentation, carbohydrate assimilation, and ChromAgar tests were used. Biofilm formation was assessed using crystal violet binding assay, while the susceptibility to antifungal agents was determined using ATBTM Fungus 3 test kits. RESULTS: The majority of Candida species were C. parapsilosis (31.3%; 31/99) and C. tropicalis (30.3%; 30/99). C. tropicalis was found to be the most frequently isolated species among all HBF Candida species. HBF Candida isolates were more frequently isolated from vaginal swab (35.7%; 10/28), tracheal aspirate (17.9%; 5/28), and urine (17.9%; 5/28). The majority of tested isolates were resistant to itraconazole and voriconazole, whereas no isolate was deemed resistant to 5-flucytosine. CONCLUSIONS: C. tropicalis displays the highest biofilm formation ability among all the Candida species evaluated, and HBF Candida isolates were more frequently seen in vaginal swab, tracheal aspirate, and urine samples. Our findings revealed that 5-flucytosine is the most efficient antifungal agent against HBF Candida isolates.
publishDate 2018
dc.date.none.fl_str_mv 2018-10-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822018000500644
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822018000500644
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/0037-8682-0136-2018
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Medicina Tropical - SBMT
publisher.none.fl_str_mv Sociedade Brasileira de Medicina Tropical - SBMT
dc.source.none.fl_str_mv Revista da Sociedade Brasileira de Medicina Tropical v.51 n.5 2018
reponame:Revista da Sociedade Brasileira de Medicina Tropical
instname:Sociedade Brasileira de Medicina Tropical (SBMT)
instacron:SBMT
instname_str Sociedade Brasileira de Medicina Tropical (SBMT)
instacron_str SBMT
institution SBMT
reponame_str Revista da Sociedade Brasileira de Medicina Tropical
collection Revista da Sociedade Brasileira de Medicina Tropical
repository.name.fl_str_mv Revista da Sociedade Brasileira de Medicina Tropical - Sociedade Brasileira de Medicina Tropical (SBMT)
repository.mail.fl_str_mv ||dalmo@rsbmt.uftm.edu.br|| rsbmt@rsbmt.uftm.edu.br
_version_ 1752122161487675392